[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344761-105":59,"doc-detail-344761-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pretreatment-mri-radiomics-for-predicting-pathological-miller-payne-grading-in-breast-cancer-following-neoadjuvant-chemotherapy-research-open-access-abstract-and-methods","Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy - Research Open Access - Abstract and methods","","Personalized management of breast cancer needs more accurate risk stratification. While many studies try to distinguish pathological complete response (pCR) from non-pCR, this does not provide sufficient prognostic prediction or treatment guidance for most non-pCR patients. This study aimed to refine neoadjuvant chemotherapy response stratification and early identification of poor responders within the non-pCR group using pretreatment MRI radiomics combined with clinical features and machine learning interpretability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pretreatment-mri-radiomics-for-predicting-pathological-miller-payne-grading-in-breast-cancer-following-neoadjuvant-chemotherapy-research-open-access-abstract-and-methods/344761/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pretreatment-mri-radiomics-for-predicting-pathological-miller-payne-grading-in-breast-cancer-following-neoadjuvant-chemotherapy-research-open-access-abstract-and-methods/344761.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study address for non-pCR breast cancer patients?","Question",{"text":112,"@type":113},"Current pCR/non-pCR classification lacks accuracy for prognostic prediction and therapy guidance among most non-pCR patients, because it overlooks heterogeneity within the non-pCR group.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was pathological response after neoadjuvant chemotherapy evaluated?",{"text":117,"@type":113},"Pathological response was assessed with the Miller-Payne grading system, where grades 1–2 indicate poor response and grades 3–5 indicate good response.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were independently associated with Miller-Payne grades?",{"text":121,"@type":113},"The radiomics score and HER2 status were independently associated with Miller-Payne grades based on logistic regression results.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344761,1790254192,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Bi etal. Cancer Imaging (2026) 26:25 [https://doi.org/10.1186/s40644-026-00990-5](https://doi.org/10.1186/s40644-026-00990-5)  \nCancer Imaging  \nRESEARCH Open Access  \nPretreatment MRI radiomics for predicting  pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy  \nChengliu Bi1†, Ao Chen1†, Fengming Ran2, Zaoxiu Hu2, Shaomei Sun1, Ruolan Wang1, Xiaofeng Niu1, Lijuan Deng1, Depei Gao1*, Qinqing Li1* and Jun Yang1*  \nAbstract  \nBackground Breast cancer’s personalized management requires better risk stratification. Recent studies focus on differentiating the pathological complete response (pCR) from non-pCR, which lacks accuracy in prognostic prediction and therapy guidance for most non-pCR patients. We aimed to better stratify neoadjuvant chemotherapy (NAC) response and early identification of poor responders in the non-pCR population.  \nMethods Pretreatment MRI scans were obtained retrospectively from breast cancer patients who had NAC followed by surgery (January 2021-October 2023) . Pathological response to NAC was assessed using the Miller-Payne (MP) grading system, with grades 1–2 indicating poor response and grades 3–5 indicating good response. Logistic regression was used to identify variables associated with MP grading and to build predictive models based on the radiomics score, clinicopathological features, and their combination. Additionally, machine learning models were also trained. The models were assessed for discrimination, calibration, and decision-making ability. Shapley Additive Explanations (SHAP) analysis was specifically performed to interpret the final machine learning model.  \nResults A total of 336 patients were included (mean age, 48.75 ± 9.52 years; training set, 235; test set, 101) . Radiomicsscore (OR = 1 .46, 95% CI: 1. 09, 1. 99; P = 0 . 013) and human epidermal growth factor receptor 2 (HER2) status (OR = 5 . 93, 95% CI: 2 . 58, 16. 16; P \u003C 0. 001) were independently associated with MP grades. The logistic regression, XGBoost, and decision tree combined models demonstrated enhanced discrimination performance, with area under the receiver operating characteristic curve (AUC) of 0.77 (95% CI: 0 . 67, 0 . 87), 0.74 (95% CI: 0 . 65, 0 . 84), and 0. 71(95% CI: 0 . 59, 0 . 82), respectively.  \nConclusions The combined model integrating pretreatment MRI radiomics score and HER2 status effectively differentiated between MP grades 1–2 and 3–5 in breast cancer following NAC. The study improved response  \n†Chengliu Bi and Ao Chen contributed equally to this work.  \n*Correspondence:  \nDepei Gao [gaodepei311@sohu.com](gaodepei311@sohu.com)[ ](gaodepei311@sohu.com)Qinqing Li [qinqing_81@163.com](qinqing_81@163.com)[ ](qinqing_81@163.com)Jun Yang [imdyang@163.com](imdyang@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creati","cbCaigVlrC2B3dwj","https://ap.wps.com/l/cbCaigVlrC2B3dwj","pdf",4580611,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Clinical and pathological assessment of NAC response\n## Limitations of current pCR/non-pCR stratification","[{\"question\":\"What clinical problem does the study address for non-pCR breast cancer patients?\",\"answer\":\"Current pCR/non-pCR classification lacks accuracy for prognostic prediction and therapy guidance among most non-pCR patients, because it overlooks heterogeneity within the non-pCR group.\"},{\"question\":\"How was pathological response after neoadjuvant chemotherapy evaluated?\",\"answer\":\"Pathological response was assessed with the Miller-Payne grading system, where grades 1–2 indicate poor response and grades 3–5 indicate good response.\"},{\"question\":\"Which factors were independently associated with Miller-Payne grades?\",\"answer\":\"The radiomics score and HER2 status were independently associated with Miller-Payne grades based on logistic regression results.\"}]","Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy - Research Open Access - Abstract and methods | PDF",1790055156,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fecaa875bf285764278fe9270df8d908.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bedc4a95e2d8530273e60869375cead5.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04ac8c9065b44f7312e13d107e72f8b4.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b42d35bc41afbbed28271cd7ac9bd618.webp",980,1306]